IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 61.38

Change

-0.13 (-0.21)%

Market Cap

N/A

Volume

0.26M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.21 (-0.14%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.04 (-0.06%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.73 (-0.68%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.13 (-1.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.20 (+0.90%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.39 (+1.23%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.33 (-0.33%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.20%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.44 (+0.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.34 (+1.61%)

USD 6.89M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.02 (+0.18%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.02 (+0.18%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.34% 62% D 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.34% 62% D 76% C+
Trailing 12 Months  
Capital Gain 1.54% 43% F 39% F
Dividend Return 1.20% 81% B- 20% F
Total Return 2.74% 52% F 30% F
Trailing 5 Years  
Capital Gain 39.04% 95% A 69% C-
Dividend Return 7.16% 74% C 20% F
Total Return 46.20% 95% A 64% D
Average Annual (5 Year Horizon)  
Capital Gain 6.05% 71% C- 54% F
Dividend Return 7.06% 76% C+ 50% F
Total Return 1.01% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 18.45% 52% F 59% D-
Risk Adjusted Return 38.25% 71% C- 52% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike